Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't

Erasca is a clinical-stage biotechnology company specializing in the development of precision oncology therapeutics for RAS/MAPK pathway-driven cancers. The company leverages a robust pipeline of targeted drug candidates and deep expertise in molecular oncology to address significant unmet medical needs. With a focused strategy on innovative cancer therapies, Erasca aims to establish a competitive edge in the rapidly evolving oncology market.Its Primary customers are anticipated to be healthcare providers, ...